Antidiabetic sulfonylureas and potassium channel openers affect the activity of the ATP-
regulated potassium channel (KATP channel) present in the plasma membrane of various …

Sulphonylureas stimulate insulin secretion from pancreatic β-cells primarily by closing ATP-
sensitive K+ channels in the β-cell plasma membrane. The mechanism of channel inhibition …

Sulphonylureas have been used for over 50 years to enhance insulin secretion in patients
with Type II (non-insulin-dependent) diabetes mellitus but their therapeutic target was not …

Sulfonylureas stimulate insulin secretion in type-2 diabetic patients by blocking ATP-
sensitive (KATP) potassium channels in the pancreatic β-cell membrane. This effect is …

Hypoglycaemic agents such as sulphonylureas and the newer group of" glinides" stimulate
insulin secretion by closing ATP-sensitive potassium (K ATP) channels in pancreatic beta …

Diabetes Mellitus is by far one of the most propagated chronic diseases, affecting 150
million people worldwide. This affliction is caused by a malfunction of pancreatic endocrine …

Aims/hypothesis: Sulphonylureas stimulate insulin secretion by closing ATP-sensitive
potassium (K ATP) channels in the pancreatic beta-cell membrane. K ATP channels are also …

Sulfonylureas are widely used to stimulate insulin secretion in type 2 diabetic patients
because they close adenosine triphosphate-sensitive potassium (KATP) channels in the …

Hypoglycaemic sulfonylureas initiate insulin secretion by direct inhibition of ATP-sensitive
K+-channels in the pancreatic β-cells. These channels are composed of two proteins, a pore …

Aims/hypothesis ATP-sensitive K+(K ATP) channels located on the beta cell plasma
membrane play a critical role in regulating insulin secretion and are targets for the …